| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $24.4M | — | -35.7% |
| SG&A Expense | $21.0M | — | +219.4% |
| Operating Income | -$45.3M | — | -2.0% |
| Net Income | -$39.3M | — | +6.8% |
| EPS (Basic) | -$0.47 | — | +40.5% |
| EPS (Diluted) | -$0.47 | — | +40.5% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $112.8M | -34.8% | -31.7% |
| Current Assets | $652.5M | -1.3% | +84.1% |
| Total Assets | $652.9M | -1.4% | +83.9% |
| Current Liabilities | $14.7M | -2.6% | +10.0% |
| Stockholders' Equity | $638.1M | -1.3% | +86.8% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$39.5M | — | +13.2% |
| Investing Cash Flow | -$44.9M | — | +51.6% |
| Financing Cash Flow | $24.3M | — | -87.2% |